FGI-104
Appearance
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
PubChemCID | |
ChemSpider | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C28H30ClN3O3 |
Molar mass | 492.02g·mol−1 |
3D model (JSmol) | |
| |
|
FGI-104is the name of an experimental broad-spectrumantiviral drug,with activity against a range of viruses includinghepatitis B,hepatitis C,HIV,Ebola virus,andVenezuelan equine encephalitis virus.[1]
Mechanism
[edit]The drug acts by inhibiting the proteinTSG101,which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice fromEbola virus disease.[2][3]
See also
[edit]References
[edit]- ^Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009)."FGI-104: a broad-spectrum small molecule inhibitor of viral infection".American Journal of Translational Research.1(1): 87–98.doi:10.1016/j.antiviral.2009.02.082.PMC2776286.PMID19966942.
- ^Janeba Z (November 2015)."Development of Small-Molecule Antivirals for Ebola".Medicinal Research Reviews.35(6): 1175–94.doi:10.1002/med.21355.PMC7168439.PMID26172225.
- ^Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.).Communicable Diseases of the Developing World.Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36.doi:10.1007/7355_2015_5003.ISBN978-3-319-78252-2.